Journal: iScience

Article Title: Drug screening to identify compounds to eliminate Burkholderia pseudomallei through Hcp protein

doi: 10.1016/j.isci.2026.115367

Figure Lengend Snippet: Netilmicin sulfate alone and in combination exerted protective effects on an infected A549 cell model (A) Cytotoxic effects of the drugs on A549 cells. (B) Protective effects of different concentrations of NETS on A549 cells. The early interventions on the abscissa reflect the incubation of A549 cells with the drug for 2 h before B. pseudomallei HNBP001 infection. Late intervention was defined as the introduction of the drug to A549 cells 2 h after infection with B. pseudomallei HNBP001 . The ordinate is the survival rate of the infected A549 cells. NC: the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Bp+30 μM NETS: The infected A549 cells were treated with 30 μM NETS; the other conditions were the same, but different concentrations of NETS were used. (C) Protective effects of several drugs on infected A549 cells; the ordinate is the survival rate of infected A549 cells. NC, blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Other: The infected A549 cells were treated with drugs (including SXT, GM, NETS, CAZ, and NETS+CAZ). (D) Number of intracellular bacteria in infected A549 cells after drug treatment; the ordinate represents the number of bacteria in infected A549 cells. NC is the blank negative control group of fresh 10% DMEM. Bp: infected A549 cell group. Drug group: 2 × MIC drug was used to treat infected A549 cells. All drugs, including SXT, GM, NETS, CAZ, and NETS+CAZ. (∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, and ∗∗∗∗ p < 0.0001; ns, no significant difference. Data are represented as mean ± SEM.).

Article Snippet: The A549 human lung carcinoma epithelial cell line was purchased from Procell (Wuhan, China; Cat# CL-0016).

Techniques: Infection, Incubation, Negative Control, Bacteria

Journal: Marine Drugs

Article Title: In Vitro Validation of Size-Dependent Antiviral Activity of Phaeodactylum tricornutum -Derived Peptide Fractions Against SARS-CoV-2

doi: 10.3390/md24040122

Figure Lengend Snippet: Cytotoxicity assessment of P. tricornutum peptide fractions in A549 cells. ( A ) Percentage of cell viability of human alveolar epithelial A549 cells treated with peptide fractions of different molecular weight ranges (10–30 kDa, 5–10 kDa, 3–5 kDa, and <3 kDa) across a concentration range of 50–1000 µg/mL. Cell viability was evaluated using MTT and resazurin assays. Differences between MTT and resazurin assays at each concentration were evaluated using two-way ANOVA followed by Šídák’s multiple comparisons test. ( B ) Heatmap representation of cell viability percentages for all peptide fractions at the indicated concentrations. Cell viability was normalized to untreated cells. Data are presented as mean ± standard deviation. ( C ) Cytotoxicity of lopinavir used as a reference control, evaluated at different concentrations expressed in µM and µg/mL. Differences among concentrations were analyzed using one-way ANOVA followed by Tukey’s post hoc test. CC 50 was determined by nonlinear regression analysis using a dose–response (variable slope) model. Statistical significance is indicated as follows: * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

Article Snippet: The human alveolar epithelial cell line A549 (ATCC CCL-185, donated by Dr. Bruno Rivas Santiago (Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico)) was used for all in vitro experiments.

Techniques: Molecular Weight, Concentration Assay, Standard Deviation, Control

Journal: Marine Drugs

Article Title: In Vitro Validation of Size-Dependent Antiviral Activity of Phaeodactylum tricornutum -Derived Peptide Fractions Against SARS-CoV-2

doi: 10.3390/md24040122

Figure Lengend Snippet: Antiviral activity of P. tricornutum peptide fractions and lopinavir against SARS-CoV-2 in A549 cells. ( A ) Percentage of SARS-CoV-2–infected cells after post-infection treatment with peptide fractions (10–30 kDa, 5–10 kDa, 3–5 kDa, and <3 kDa) at concentrations of 100, 300, and 500 µg/mL, and with lopinavir (control) at the indicated concentrations expressed in µM and µg/mL. ( B ) Comparison of infection percentages grouped by concentration across all peptide fractions. Data are expressed as mean ± standard deviation. Statistical significance was determined by one-way ANOVA followed by Tukey’s post hoc test. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001; ns, not significant.

Article Snippet: The human alveolar epithelial cell line A549 (ATCC CCL-185, donated by Dr. Bruno Rivas Santiago (Unidad de Investigación Biomédica de Zacatecas, Instituto Mexicano del Seguro Social, Zacatecas 98000, Mexico)) was used for all in vitro experiments.

Techniques: Activity Assay, Infection, Control, Comparison, Concentration Assay, Standard Deviation